OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
FDA sticks with approved vaccine dosing regimen; supply agreements announced
Biopharma looks to deliver on COVID-19 vaccines and other promising therapies.
Annual employment survey reveals more dedication but fewer financial rewards.
January 21, 2021
The approval was based on positive results from a single-arm Phase II trial where the treatment demonstrated significant antitumor activities in patients with the disease.
January 20, 2021
The companies will develop up to three CD3-engaging T-cell redirecting bispecific antibody therapies using Merus' proprietary Biclonics platform.
Leveraging real-time MRI guidance for intracranial gene therapy administration potentially improves efficacy and outcomes.
Through the acquisition, Thermo Fisher will have access to Mesa’s PCR-based rapid point-of-care testing platform for detecting infectious diseases.
January 19, 2021
The new US offices will give the company the ability to support its US-based customers on site while continuing to collaborate with its global team.
Since FDA authorization of two innovative mRNA vaccines to combat COVID-19 in late 2020, 30 million doses have been distributed, but only 4 million people were vaccinated in December 2020, and just 13 million have received shots so far.
The CPhI event, which was originally scheduled for Aug. 31–Sept. 2, 2021 at the Fiera Milano in Milan, Italy, will be rescheduled for Nov. 9–11, 2021 at the same venue.
January 18, 2021
The 40,000-ft.2 facility will feature eight cleanrooms with configurations for the production of cell and viral vector products.
Henogen will be integrated into Thermo Fisher’s Pharma Services business within its Laboratory Products and Services segment.
January 15, 2021
This new agreement covers 1.25 million additional doses of the antibody cocktail containing casirivimab and imdevimab for the treatment of COVID-19.
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
The first four investments of the new program will support clinical-stage biotechnology companies while new investments will include companies focused on oncology, rare disease, and inflammation and immunology.